EGFR and non-small cell lung carcinoma: conducted a network meta-analysis that included data from 3539 EGFR mutation-positive NSCLC patients, comparing five EGFR-TKIs, including Afatinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in first-line treatment (55).